Candesartan improves impaired endothelial function in the human coronary artery
BACKGROUNDEndothelial dysfunction is closely related to cardiovascular events. Several studies have documented that angiotensin II type 1 receptor blockers (ARB) improve peripheral endothelial dysfunction. However, the effect of ARB on coronary endothelial function remains elusive. The purpose of th...
Gespeichert in:
| Veröffentlicht in: | Coronary artery disease 2012-06, Vol.23 (4), p.278-283 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 283 |
|---|---|
| container_issue | 4 |
| container_start_page | 278 |
| container_title | Coronary artery disease |
| container_volume | 23 |
| creator | Iino, Kenji Watanabe, Hiroyuki Iino, Takako Katsuta, Mitsuaki Koyama, Takashi Kosaka, Toshimitsu Terui, Gen Ito, Hiroshi |
| description | BACKGROUNDEndothelial dysfunction is closely related to cardiovascular events. Several studies have documented that angiotensin II type 1 receptor blockers (ARB) improve peripheral endothelial dysfunction. However, the effect of ARB on coronary endothelial function remains elusive. The purpose of this study was to ascertain the beneficial effects of ARB on human coronary artery endothelial function.
METHODS AND RESULTSTwenty-seven patients were randomly assigned to either the candesartan group (n=14) or the control group (n=13) and followed for 12 months. Coronary blood flow velocity was measured in the left anterior descending artery without stenosis using an intracoronary Doppler-tipped guide-wire. We evaluated coronary endothelial function as the coronary blood flow velocity reserve (CFR), which was defined as the percent change in the coronary blood flow velocity after an intracoronary acetylcholine infusion. At baseline, the CFR in both groups was below 300%, implying that these patients had endothelial dysfunction. After treatment with candesartan for 6 months, the CFR increased significantly from 199±20 to 337±27% (P |
| doi_str_mv | 10.1097/MCA.0b013e328351ab42 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1010495154</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1010495154</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3562-3c2d5c24ae7131bda6152182beb525fee6ee1902dcd839ebdd9f8ac6810673ee3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwBwhlySbFzyReVhUvqagbWEeOPVECTlzshKp_j6sWFixYzWh07p2Zi9A1wXOCZX73slzMcYUJA0YLJoiqOD1BU8JzloqC4VM0xVLwNJO0mKCLEN4xJlzk4hxNKGWc5VJO0XqpegNB-UH1SdttvPuCsG9U68Ek0Bs3NGBbZZN67PXQuoj1SZwlzdhFjXbe9crvkmgBfneJzmplA1wd6wy9Pdy_Lp_S1frxeblYpZqJjKZMUyM05QpywkhlVEYEJQWtoBJU1AAZAJGYGm0KJqEyRtaF0llBcJYzADZDtwffePHnCGEouzZosFb14MZQEkwwl4IIHlF-QLV3IXioy41vu3hyhMp9lGWMsvwbZZTdHDeMVQfmV_STXQSKA7B1Nr4ePuy4BV82oOzQ_O_9DZ66g3M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1010495154</pqid></control><display><type>article</type><title>Candesartan improves impaired endothelial function in the human coronary artery</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Iino, Kenji ; Watanabe, Hiroyuki ; Iino, Takako ; Katsuta, Mitsuaki ; Koyama, Takashi ; Kosaka, Toshimitsu ; Terui, Gen ; Ito, Hiroshi</creator><creatorcontrib>Iino, Kenji ; Watanabe, Hiroyuki ; Iino, Takako ; Katsuta, Mitsuaki ; Koyama, Takashi ; Kosaka, Toshimitsu ; Terui, Gen ; Ito, Hiroshi</creatorcontrib><description>BACKGROUNDEndothelial dysfunction is closely related to cardiovascular events. Several studies have documented that angiotensin II type 1 receptor blockers (ARB) improve peripheral endothelial dysfunction. However, the effect of ARB on coronary endothelial function remains elusive. The purpose of this study was to ascertain the beneficial effects of ARB on human coronary artery endothelial function.
METHODS AND RESULTSTwenty-seven patients were randomly assigned to either the candesartan group (n=14) or the control group (n=13) and followed for 12 months. Coronary blood flow velocity was measured in the left anterior descending artery without stenosis using an intracoronary Doppler-tipped guide-wire. We evaluated coronary endothelial function as the coronary blood flow velocity reserve (CFR), which was defined as the percent change in the coronary blood flow velocity after an intracoronary acetylcholine infusion. At baseline, the CFR in both groups was below 300%, implying that these patients had endothelial dysfunction. After treatment with candesartan for 6 months, the CFR increased significantly from 199±20 to 337±27% (P<0.001), whereas the CFR did not change in the control group (194±32 vs. 185±41%, P=0.52). During 12 months of observation, the cardiovascular event-free survival rate of the patients with an increased CFR was significantly greater than the rate in patients with a decreased CFR (P=0.02). Moreover, the cardiovascular event-free survival rate was greater in the candesartan group than in the control group (P=0.04).
CONCLUSIONOur results suggest that candesartan improves coronary endothelial dysfunction of human coronary arteries and may prevent cardiac events.</description><identifier>ISSN: 0954-6928</identifier><identifier>EISSN: 1473-5830</identifier><identifier>DOI: 10.1097/MCA.0b013e328351ab42</identifier><identifier>PMID: 22343799</identifier><language>eng</language><publisher>England: Lippincott Williams & Wilkins, Inc</publisher><subject>Aged ; Angiotensin II Type 1 Receptor Blockers - administration & dosage ; Benzimidazoles - administration & dosage ; Blood Flow Velocity - drug effects ; Blood Flow Velocity - physiology ; Coronary Artery Disease - drug therapy ; Coronary Artery Disease - physiopathology ; Coronary Circulation - drug effects ; Coronary Circulation - physiology ; Coronary Vessels - drug effects ; Coronary Vessels - physiopathology ; Disease-Free Survival ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - physiopathology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Tetrazoles - administration & dosage ; Treatment Outcome ; Ultrasonography, Doppler</subject><ispartof>Coronary artery disease, 2012-06, Vol.23 (4), p.278-283</ispartof><rights>2012 Lippincott Williams & Wilkins, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3562-3c2d5c24ae7131bda6152182beb525fee6ee1902dcd839ebdd9f8ac6810673ee3</citedby><cites>FETCH-LOGICAL-c3562-3c2d5c24ae7131bda6152182beb525fee6ee1902dcd839ebdd9f8ac6810673ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22343799$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Iino, Kenji</creatorcontrib><creatorcontrib>Watanabe, Hiroyuki</creatorcontrib><creatorcontrib>Iino, Takako</creatorcontrib><creatorcontrib>Katsuta, Mitsuaki</creatorcontrib><creatorcontrib>Koyama, Takashi</creatorcontrib><creatorcontrib>Kosaka, Toshimitsu</creatorcontrib><creatorcontrib>Terui, Gen</creatorcontrib><creatorcontrib>Ito, Hiroshi</creatorcontrib><title>Candesartan improves impaired endothelial function in the human coronary artery</title><title>Coronary artery disease</title><addtitle>Coron Artery Dis</addtitle><description>BACKGROUNDEndothelial dysfunction is closely related to cardiovascular events. Several studies have documented that angiotensin II type 1 receptor blockers (ARB) improve peripheral endothelial dysfunction. However, the effect of ARB on coronary endothelial function remains elusive. The purpose of this study was to ascertain the beneficial effects of ARB on human coronary artery endothelial function.
METHODS AND RESULTSTwenty-seven patients were randomly assigned to either the candesartan group (n=14) or the control group (n=13) and followed for 12 months. Coronary blood flow velocity was measured in the left anterior descending artery without stenosis using an intracoronary Doppler-tipped guide-wire. We evaluated coronary endothelial function as the coronary blood flow velocity reserve (CFR), which was defined as the percent change in the coronary blood flow velocity after an intracoronary acetylcholine infusion. At baseline, the CFR in both groups was below 300%, implying that these patients had endothelial dysfunction. After treatment with candesartan for 6 months, the CFR increased significantly from 199±20 to 337±27% (P<0.001), whereas the CFR did not change in the control group (194±32 vs. 185±41%, P=0.52). During 12 months of observation, the cardiovascular event-free survival rate of the patients with an increased CFR was significantly greater than the rate in patients with a decreased CFR (P=0.02). Moreover, the cardiovascular event-free survival rate was greater in the candesartan group than in the control group (P=0.04).
CONCLUSIONOur results suggest that candesartan improves coronary endothelial dysfunction of human coronary arteries and may prevent cardiac events.</description><subject>Aged</subject><subject>Angiotensin II Type 1 Receptor Blockers - administration & dosage</subject><subject>Benzimidazoles - administration & dosage</subject><subject>Blood Flow Velocity - drug effects</subject><subject>Blood Flow Velocity - physiology</subject><subject>Coronary Artery Disease - drug therapy</subject><subject>Coronary Artery Disease - physiopathology</subject><subject>Coronary Circulation - drug effects</subject><subject>Coronary Circulation - physiology</subject><subject>Coronary Vessels - drug effects</subject><subject>Coronary Vessels - physiopathology</subject><subject>Disease-Free Survival</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Tetrazoles - administration & dosage</subject><subject>Treatment Outcome</subject><subject>Ultrasonography, Doppler</subject><issn>0954-6928</issn><issn>1473-5830</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EoqXwBwhlySbFzyReVhUvqagbWEeOPVECTlzshKp_j6sWFixYzWh07p2Zi9A1wXOCZX73slzMcYUJA0YLJoiqOD1BU8JzloqC4VM0xVLwNJO0mKCLEN4xJlzk4hxNKGWc5VJO0XqpegNB-UH1SdttvPuCsG9U68Ek0Bs3NGBbZZN67PXQuoj1SZwlzdhFjXbe9crvkmgBfneJzmplA1wd6wy9Pdy_Lp_S1frxeblYpZqJjKZMUyM05QpywkhlVEYEJQWtoBJU1AAZAJGYGm0KJqEyRtaF0llBcJYzADZDtwffePHnCGEouzZosFb14MZQEkwwl4IIHlF-QLV3IXioy41vu3hyhMp9lGWMsvwbZZTdHDeMVQfmV_STXQSKA7B1Nr4ePuy4BV82oOzQ_O_9DZ66g3M</recordid><startdate>201206</startdate><enddate>201206</enddate><creator>Iino, Kenji</creator><creator>Watanabe, Hiroyuki</creator><creator>Iino, Takako</creator><creator>Katsuta, Mitsuaki</creator><creator>Koyama, Takashi</creator><creator>Kosaka, Toshimitsu</creator><creator>Terui, Gen</creator><creator>Ito, Hiroshi</creator><general>Lippincott Williams & Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201206</creationdate><title>Candesartan improves impaired endothelial function in the human coronary artery</title><author>Iino, Kenji ; Watanabe, Hiroyuki ; Iino, Takako ; Katsuta, Mitsuaki ; Koyama, Takashi ; Kosaka, Toshimitsu ; Terui, Gen ; Ito, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3562-3c2d5c24ae7131bda6152182beb525fee6ee1902dcd839ebdd9f8ac6810673ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Angiotensin II Type 1 Receptor Blockers - administration & dosage</topic><topic>Benzimidazoles - administration & dosage</topic><topic>Blood Flow Velocity - drug effects</topic><topic>Blood Flow Velocity - physiology</topic><topic>Coronary Artery Disease - drug therapy</topic><topic>Coronary Artery Disease - physiopathology</topic><topic>Coronary Circulation - drug effects</topic><topic>Coronary Circulation - physiology</topic><topic>Coronary Vessels - drug effects</topic><topic>Coronary Vessels - physiopathology</topic><topic>Disease-Free Survival</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Tetrazoles - administration & dosage</topic><topic>Treatment Outcome</topic><topic>Ultrasonography, Doppler</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Iino, Kenji</creatorcontrib><creatorcontrib>Watanabe, Hiroyuki</creatorcontrib><creatorcontrib>Iino, Takako</creatorcontrib><creatorcontrib>Katsuta, Mitsuaki</creatorcontrib><creatorcontrib>Koyama, Takashi</creatorcontrib><creatorcontrib>Kosaka, Toshimitsu</creatorcontrib><creatorcontrib>Terui, Gen</creatorcontrib><creatorcontrib>Ito, Hiroshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Coronary artery disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Iino, Kenji</au><au>Watanabe, Hiroyuki</au><au>Iino, Takako</au><au>Katsuta, Mitsuaki</au><au>Koyama, Takashi</au><au>Kosaka, Toshimitsu</au><au>Terui, Gen</au><au>Ito, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Candesartan improves impaired endothelial function in the human coronary artery</atitle><jtitle>Coronary artery disease</jtitle><addtitle>Coron Artery Dis</addtitle><date>2012-06</date><risdate>2012</risdate><volume>23</volume><issue>4</issue><spage>278</spage><epage>283</epage><pages>278-283</pages><issn>0954-6928</issn><eissn>1473-5830</eissn><abstract>BACKGROUNDEndothelial dysfunction is closely related to cardiovascular events. Several studies have documented that angiotensin II type 1 receptor blockers (ARB) improve peripheral endothelial dysfunction. However, the effect of ARB on coronary endothelial function remains elusive. The purpose of this study was to ascertain the beneficial effects of ARB on human coronary artery endothelial function.
METHODS AND RESULTSTwenty-seven patients were randomly assigned to either the candesartan group (n=14) or the control group (n=13) and followed for 12 months. Coronary blood flow velocity was measured in the left anterior descending artery without stenosis using an intracoronary Doppler-tipped guide-wire. We evaluated coronary endothelial function as the coronary blood flow velocity reserve (CFR), which was defined as the percent change in the coronary blood flow velocity after an intracoronary acetylcholine infusion. At baseline, the CFR in both groups was below 300%, implying that these patients had endothelial dysfunction. After treatment with candesartan for 6 months, the CFR increased significantly from 199±20 to 337±27% (P<0.001), whereas the CFR did not change in the control group (194±32 vs. 185±41%, P=0.52). During 12 months of observation, the cardiovascular event-free survival rate of the patients with an increased CFR was significantly greater than the rate in patients with a decreased CFR (P=0.02). Moreover, the cardiovascular event-free survival rate was greater in the candesartan group than in the control group (P=0.04).
CONCLUSIONOur results suggest that candesartan improves coronary endothelial dysfunction of human coronary arteries and may prevent cardiac events.</abstract><cop>England</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>22343799</pmid><doi>10.1097/MCA.0b013e328351ab42</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-6928 |
| ispartof | Coronary artery disease, 2012-06, Vol.23 (4), p.278-283 |
| issn | 0954-6928 1473-5830 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1010495154 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Aged Angiotensin II Type 1 Receptor Blockers - administration & dosage Benzimidazoles - administration & dosage Blood Flow Velocity - drug effects Blood Flow Velocity - physiology Coronary Artery Disease - drug therapy Coronary Artery Disease - physiopathology Coronary Circulation - drug effects Coronary Circulation - physiology Coronary Vessels - drug effects Coronary Vessels - physiopathology Disease-Free Survival Endothelium, Vascular - drug effects Endothelium, Vascular - physiopathology Female Follow-Up Studies Humans Male Middle Aged Tetrazoles - administration & dosage Treatment Outcome Ultrasonography, Doppler |
| title | Candesartan improves impaired endothelial function in the human coronary artery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T23%3A10%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Candesartan%20improves%20impaired%20endothelial%20function%20in%20the%20human%20coronary%20artery&rft.jtitle=Coronary%20artery%20disease&rft.au=Iino,%20Kenji&rft.date=2012-06&rft.volume=23&rft.issue=4&rft.spage=278&rft.epage=283&rft.pages=278-283&rft.issn=0954-6928&rft.eissn=1473-5830&rft_id=info:doi/10.1097/MCA.0b013e328351ab42&rft_dat=%3Cproquest_cross%3E1010495154%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1010495154&rft_id=info:pmid/22343799&rfr_iscdi=true |